HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and raised the price target from $41 to $45.
August 15, 2024 | 5:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Syndax Pharmaceuticals and raised the price target from $41 to $45.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100